Barbara Davis Center, Division of Pediatric Endocrinology, Department of Pediatrics, University of Colorado Denver, Denver, Colorado, USA.
International Diabetes Center, HealthPartners Institute, Minneapolis, Minnesota, USA.
Diabetes Technol Ther. 2022 Nov;24(11):814-823. doi: 10.1089/dia.2022.0206. Epub 2022 Jul 26.
The Tandem Control-IQ (CIQ) system has demonstrated significant glycemic improvements in large randomized controlled and real-world trials. Use of this system is lower in people with type 1 diabetes (T1D) government-sponsored insurance and those with type 2 diabetes (T2D). This analysis aimed to evaluate the performance of CIQ in these groups. A retrospective analysis of CIQ users was performed. Users age ≥6 years with a t:slim X2 Pump and >30 days of continuous glucose monitoring (CGM) data pre-CIQ and >30 days post-CIQ technology initiation were included. A total of 4243 Medicare and 1332 Medicaid CIQ users were analyzed among whom 5075 had T1D and 500 had T2D. After starting CIQ, the Medicare beneficiaries group saw significant improvement in time in target range 70-180 mg/dL (TIR; 64% vs. 74%; < 0.0001), glucose management index (GMI; 7.3% vs. 7.0%; < 0.0001), and the percentage of users meeting American Diabetes Association (ADA) CGM Glucometrics Guidelines (12.8% vs. 26.3%; < 0.0001). The Medicaid group also saw significant improvement in TIR (46% vs. 60%; < 0.0001), GMI (7.9% vs. 7.5%; < 0.0001), and percentage meeting ADA guidelines (5.7% vs. 13.4%; < 0.0001). Patients with T2D and either insurance saw significant glycemic improvements. The CIQ system was effective in the Medicare and Medicaid groups in improving glycemic control. The T2D subgroup also demonstrated improved glycemic control with CIQ use. Glucometrics achieved in this analysis are comparable with those seen in previous randomized controlled clinical trials with the CIQ system.
Tandem Control-IQ（CIQ）系统在大型随机对照试验和真实世界研究中显示出显著的血糖改善效果。在有 1 型糖尿病（T1D）政府医疗保险和 2 型糖尿病（T2D）的人群中，该系统的使用率较低。本分析旨在评估 CIQ 在这些人群中的表现。对 CIQ 用户进行了回顾性分析。纳入使用 t:slim X2 泵且有连续血糖监测（CGM）数据≥6 年的患者，CIQ 使用前 CGM 数据≥30 天，CIQ 使用后 CGM 数据≥30 天。共分析了 4243 名 Medicare 和 1332 名 Medicaid 的 CIQ 用户，其中 5075 名患有 T1D，500 名患有 T2D。开始使用 CIQ 后，Medicare 受益人群的目标范围内时间（70-180mg/dL）显著增加（64% vs. 74%；<0.0001），血糖管理指数（GMI）也显著增加（7.3% vs. 7.0%；<0.0001），符合美国糖尿病协会（ADA）CGM 血糖监测标准的用户比例也显著增加（12.8% vs. 26.3%；<0.0001）。Medicaid 人群的 TIR（46% vs. 60%；<0.0001）、GMI（7.9% vs. 7.5%；<0.0001）和符合 ADA 指南的比例（5.7% vs. 13.4%；<0.0001）也显著增加。患有 T2D 且有任意一种保险的患者血糖都有显著改善。CIQ 系统在 Medicare 和 Medicaid 人群中可有效改善血糖控制。T2D 亚组使用 CIQ 也可改善血糖控制。本分析中实现的血糖监测结果与 CIQ 系统之前的随机对照临床试验结果相当。
